SPP1 and metabolic dysfunction-associated steatotic liver disease: Several animal studies and clinical trials have demonstrated that SPP1 mediates chronic inflammation and promotes hepatic lipid accumulation and fibrosis, thereby supporting its role in enhancing the development of NAFLD [86,88].